OBJECTIVES: ATM is an important protein that protects the genome from double-stranded DNA breaks. Mutations and polymorphisms in the ATM gene have been associated with an increased risk of certain types of malignancies, especially breast cancer. METHODS: We analyzed tissue from 98 white patients with prostate cancer for the presence of IVS62+60G>A polymorphism in the ATM gene. RESULTS: The frequency of the homozygous IVS62+60G/G, heterozygous IVS62+60G/A, and homozygous IVS62+60A/A was 18.37% (18 of 98), 30.61% (30 of 98), and 51.02% (50 of 98), respectively. Using Fisher's exact test, we found the polymorphism IVS62+60G>A was not significantly related to age, tumor grade, prostate-specific antigen level, or clinical stage (P >0.05). No difference was found in relapse-free survival between patients with IVS62+60G/G and those with IVS62+60G/A or IVS62+60A/A (P = 0.4533). CONCLUSIONS: The results of our study indicate that this ATM polymorphism is not associated with the aggressiveness of prostate cancer in white men.
OBJECTIVES:ATM is an important protein that protects the genome from double-stranded DNA breaks. Mutations and polymorphisms in the ATM gene have been associated with an increased risk of certain types of malignancies, especially breast cancer. METHODS: We analyzed tissue from 98 white patients with prostate cancer for the presence of IVS62+60G>A polymorphism in the ATM gene. RESULTS: The frequency of the homozygous IVS62+60G/G, heterozygous IVS62+60G/A, and homozygous IVS62+60A/A was 18.37% (18 of 98), 30.61% (30 of 98), and 51.02% (50 of 98), respectively. Using Fisher's exact test, we found the polymorphism IVS62+60G>A was not significantly related to age, tumor grade, prostate-specific antigen level, or clinical stage (P >0.05). No difference was found in relapse-free survival between patients with IVS62+60G/G and those with IVS62+60G/A or IVS62+60A/A (P = 0.4533). CONCLUSIONS: The results of our study indicate that this ATM polymorphism is not associated with the aggressiveness of prostate cancer in white men.
Authors: Jerry J Jaboin; Misun Hwang; Zachary Lopater; Heidi Chen; Geoffrey L Ray; Carmen Perez; Qiuyin Cai; Marcia L Wills; Bo Lu Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-03 Impact factor: 7.038
Authors: Carmen A Perez; Heidi Chen; Yu Shyr; Regina Courtney; Wei Zheng; Qiuyin Cai; Misun Hwang; Jerry Jaboin; Stephen Schleicher; Luigi Moretti; Marcia Wills; Joseph A Smith; Bo Lu Journal: J Urol Date: 2010-03-19 Impact factor: 7.450
Authors: Taro Okazaki; Li Jiao; Ping Chang; Douglas B Evans; James L Abbruzzese; Donghui Li Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Jerry J Jaboin; Misun Hwang; Carmen A Perez; Calvin Cooper; Heidi Chen; Chuanzhong Ye; Qiuyin Cai; Marcia L Wills; Bo Lu Journal: Urol Oncol Date: 2009-06-12 Impact factor: 3.498
Authors: Luis Alberto Henríquez-Hernández; Almudena Valenciano; Palmira Foro-Arnalot; María Jesús Álvarez-Cubero; José Manuel Cozar; José Francisco Suárez-Novo; Manel Castells-Esteve; Pablo Fernández-Gonzalo; Belén De-Paula-Carranza; Montse Ferrer; Ferrán Guedea; Gemma Sancho-Pardo; Jordi Craven-Bartle; María José Ortiz-Gordillo; Patricia Cabrera-Roldán; Estefanía Herrera-Ramos; Carlos Rodríguez-Gallego; Juan Ignacio Rodríguez-Melcón; Pedro C Lara Journal: BMC Med Genet Date: 2014-12-24 Impact factor: 2.103
Authors: Shona H Lang; Stephanie L Swift; Heath White; Kate Misso; Jos Kleijnen; Ruben G W Quek Journal: Int J Oncol Date: 2019-07-16 Impact factor: 5.650